• Celcuity (NasdaqCM:CELC) amended its pivotal Phase 3 VIKTORIA-2 trial to add a new cohort for endocrine-sensitive breast cancer.
• The company is also developing a subcutaneous formulation of gedatolisib to offer a more convenient treatment option.
• These updates extend the clinical reach of VIKTORIA-2 beyond previously discussed trial and financing milestones.

For investors tracking Celcuity, the latest clinical updates come after a sharp pullback in the share price, which is down 29.4% over the past week and 34.7% over the past month to around $92.47. Even after that volatility, the stock has delivered a very large gain over the past year, reflecting how much expectations around gedatolisib matter for NasdaqCM:CELC.

By adding endocrine-sensitive patients and working on a subcutaneous formulation, Celcuity is aiming to widen the potential use of its lead asset and make treatment less burdensome for patients. How these efforts translate into future trial readouts, regulatory discussions, and eventual commercial conversations is likely to be an important focus for anyone following NasdaqCM:CELC from here.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Quick Assessment

• ✅ Price vs Analyst Target: At around US$92.47, the stock trades roughly 43% below the US$161.09 analyst price target.
• ✅ Simply Wall St Valuation: Simply Wall St flags Celcuity as trading about 88.9% below its estimated fair value.
• ❌ Recent Momentum: The share price has fallen 34.7% over the past 30 days, indicating weak short term sentiment.

The decision to buy, sell or hold Celcuity depends on your own objectives and risk tolerance. For more detail, visit Simply Wall St's company report for the latest analysis of Celcuity's fair value.

Key Considerations

• 📊 Expanding VIKTORIA-2 to endocrine-sensitive patients and pursuing a subcutaneous gedatolisib formulation may broaden how the lead asset could be used if trials are successful.
• 📊 Monitor upcoming VIKTORIA-2 milestones, cash usage and any updates on regulatory timelines alongside the current analyst target of US$161.09.
• ⚠️ Celcuity currently reports less than US$1m in revenue and remains loss making, so outcomes depend heavily on clinical and funding progress.

Dig Deeper

For a fuller picture, including additional risks and potential rewards, explore the complete Celcuity analysis. You can also visit the community page for Celcuity to see how other investors believe this latest news fits into the company's overall narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.